Vir Biotechnology (VIR) Deferred Taxes (2018 - 2024)
Vir Biotechnology's (VIR) quarterly Deferred Taxes came in at -$2.6 million in Q4 2024, down 148.64% year-on-year from $5.4 million in Q1 2024, and down 4736.84% quarter-over-quarter from $57000.0 in Q3 2024.
Vir Biotechnology (VIR) Deferred Taxes (2018 - 2024) Analysis & Trends
Vir Biotechnology has disclosed Deferred Taxes across 3 years of filings, most recently posting -$2.6 million for Q4 2024.
- Deferred Taxes for Q4 2024 came in at -$2.6 million, down 148.64% year-over-year; the trailing twelve-month figure through Dec 2024 was -$3.6 million (changed N/A YoY), and the FY2024 annual result was -$2.9 million, down 177.42% from the prior year.
- Deferred Taxes came in at -$2.6 million for Q4 2024 at Vir Biotechnology, down from $57000.0 in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $57000.0 in Q3 2024 to a low of -$2.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -859,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -65.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Vir Biotechnology | 1.35 Bn | 1.35 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2.64 Mn |
| Sep 30, 2024 | 57,000.00 |
| Dec 31, 2023 | -1.06 Mn |
| Dec 31, 2018 | 980,000.00 |